Ji. Berger et al., EFFECT OF AMRINONE DURING GROUP-B STREPTOCOCCUS-INDUCED PULMONARY-HYPERTENSION IN PIGLETS, Pediatric pulmonology, 16(5), 1993, pp. 303-310
Intravenous infusion of group B Streptococcus (GBS) into neonatal anim
als produces pulmonary hypertension, ventilation/perfusion (V(A)/Q mis
match, and an increase in serum levels of thromboxane B2 (TxB2) and tu
mor necrosis factor (TNF)alpha. The vasodilator amrinone (amr) is a cG
MP-inhibited phosphodiesterase inhibitor and is reported to inhibit th
romboxane A2 and TNF production. We hypothesized that infusion of amr
would cause pulmonary vasodilation and reduce serum TxB2 and TNF level
s in piglets with late phase GBS-induced pulmonary hypertension. The e
ffect of amr on gas exchange was also determined. A continuous infusio
n of GBS was administered for 5 hr to 4 groups of anesthetized, mechan
ically ventilated neonatal piglets. An amr bolus of 8 mg/kg was given
at 4 hr followed by a 1 hr continuous infusion of either 10 or 20 mug/
kg/min of amr (amr 10 and amr 20, respectively). Control piglets recei
ved a bolus and 1 hr infusion of amr carrier. The infusion of amr, but
not of carrier reversed late phase GBS-induced pulmonary hypertension
. Piglets infused with amr 20 showed transient selective pulmonary vas
odilation, based on a reduced ratio of pulmonary to systemic vascular
resistance (PVR/SVR ratio) value at 30 min but not at 1 hr, compared t
o pre-amr treatment values. The PVR/SVR ratio values for amr 10 and co
ntrol group did not change after treatment with either amr or carrier.
Treatment with amr 10 or 20 did not decrease serum TxB, or TNF levels
or increase V(A)/Q mismatch. A subsequent group of piglets received a
n 8 mg/kg bolus and 40 mug/kg/min infusion of amr (amr 40) to determin
e if the increased infusion rate would sustain a selective pulmonary v
asodilatory effect beyond 30 min. The PVR/SVR ratio values for amr 40
did not change after treatment for 30 min or 1 hr, compared to pretrea
tment values. We conclude that amr is effective in reversing GBS-induc
ed pulmonary hypertension. However, the reduction in SVR caused by amr
may preclude its use in septic newborns. (C) 1993 Wiley-Liss, Inc.